source
- Eli Lilly’s one-patient early access to retatrutide leaves doctors seeking answersEli Lilly granted a single 79-year-old patient special access to retatrutide, an experimental obesity drug that has shown weight‑loss results comparable to bariatric surgery. Since that decision,…
- BioNTech appoints Sobi head Guido Oelkers as new CEO to steer oncology shiftBioNTech announced that Guido Oelkers, who has led the rare‑disease focused Swedish company Sobi since 2017, will become its next chief executive officer. Oelkers is slated to take over the role b…